Loading…

Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer

The prognostic value of tissue-type plasminogen activator (tPA) measured in samples derived from 865 patients with primary breast cancer using a recently developed enzyme-linked immunosorbent assay (ELISA) was evaluated. Since the assay could easily be adapted to the assessment of the complex of tPA...

Full description

Saved in:
Bibliographic Details
Published in:British Journal of Cancer 1999-04, Vol.80 (1-2), p.286-294
Main Authors: Witte, J H de, Sweep, C G J, Klijn, J G M, Grebenschikov, N, Peters, H A, Look, M P, Tienoven, ThH van, Heuvel, J J T M, Vries, J Bolt-De, Benraad, ThJ, Foekens, J A
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c477t-4e58ff0158b743159401de9a5bf6fb428e2e31b5ae49348124e634959aebe8993
cites cdi_FETCH-LOGICAL-c477t-4e58ff0158b743159401de9a5bf6fb428e2e31b5ae49348124e634959aebe8993
container_end_page 294
container_issue 1-2
container_start_page 286
container_title British Journal of Cancer
container_volume 80
creator Witte, J H de
Sweep, C G J
Klijn, J G M
Grebenschikov, N
Peters, H A
Look, M P
Tienoven, ThH van
Heuvel, J J T M
Vries, J Bolt-De
Benraad, ThJ
Foekens, J A
description The prognostic value of tissue-type plasminogen activator (tPA) measured in samples derived from 865 patients with primary breast cancer using a recently developed enzyme-linked immunosorbent assay (ELISA) was evaluated. Since the assay could easily be adapted to the assessment of the complex of tPA with its type-1 inhibitor (PAI-1), it was investigated whether the tPA:PAI-1 complex also provides prognostic information. To this end, cytosolic extracts and corresponding detergent extracts of 100 000 g pellets obtained after ultracentrifugation when preparing the cytosolic fractions for routine steroid hormone receptor determination were assayed. Statistically significant correlations were found between the cytosolic levels and those determined in the pellet extracts (Spearman correlation coefficient r s = 0.75, P < 0.001 for tPA and r = 0.50, P < 0.001 for tPA:PAI-1 complex). In both Cox univariate and multivariate analysis elevated levels of (total) tPA determined in the pellet extracts, but not in cytosols, were associated with prolonged relapse-free (RFS) and overall survival (OS). In contrast, high levels of the tPA:PAI-1 complex measured in cytosols, but not in the pellet extracts, were associated with a poor RFS and OS. The prognostic information provided by the cytosolic tPA:PAI-1 complex was comparable to that provided by cytosolic (total) PAI-1. Furthermore, the estimated levels of free, uncomplexed tPA and PAI-1, in cytosols and in pellet extracts, were related to patient prognosis in a similar way as the (total) levels of tPA and PAI-1 respectively. Determination of specific forms of components of the plasminogen activation system, i.e. tPA:PAI-1 complex and free, uncomplexed tPA and/or PAI-1, may be considered a useful adjunct to the analyses of the separate components (tPA and/or PAI-1) and provide valuable additional prognostic information with respect to survival of breast cancer patients.
doi_str_mv 10.1038/sj.bjc.6690353
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2362996</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69859634</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-4e58ff0158b743159401de9a5bf6fb428e2e31b5ae49348124e634959aebe8993</originalsourceid><addsrcrecordid>eNp1kc9v0zAcxS0EYqVw5QbyASF2SGfHdhJfJlUTPyZNogc4W477TesosYvtFHbhb8cjZYwDJ8t-n_e-X_kh9JKSFSWsuYj9qu3NqqokYYI9QgvK66oQrKGP0YIQUhdEluQMPYuxJySLtXiKzrJV5htZoJ-b4HfOx2QNPuphAuw7nGyMExTp9gD4MOg4Wud34LA2yR518gG_S5v1OdZui22K2PjxMMAP_N2mPU57wHfOgmLr9ra1v_nN-rqg5_kFtwF0TNhoZyA8R086PUR4cTqX6OuH91-uPhU3nz9eX61vCpM3TgUH0XQdoaJpa86okJzQLUgt2q7qWl42UAKjrdDAJeMNLTlUjEshNbTQSMmW6HLOPUztCFsDLgU9qEOwow63ymur_lWc3audP6qSVaWUVQ54ewoI_tsEManRRgPDoB34KapKNiJjPIOrGTTBxxigux9CibqrTMVe5crUqbJseP1wtQf43FEG3pwAHY0eupB_zsa_XN00dQ5aoosZi1lxOwiq91Nw-Vf_P_nV7HA6TQHuE__ovwC7pbpJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69859634</pqid></control><display><type>article</type><title>Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer</title><source>Wiley</source><source>PubMed Central</source><creator>Witte, J H de ; Sweep, C G J ; Klijn, J G M ; Grebenschikov, N ; Peters, H A ; Look, M P ; Tienoven, ThH van ; Heuvel, J J T M ; Vries, J Bolt-De ; Benraad, ThJ ; Foekens, J A</creator><creatorcontrib>Witte, J H de ; Sweep, C G J ; Klijn, J G M ; Grebenschikov, N ; Peters, H A ; Look, M P ; Tienoven, ThH van ; Heuvel, J J T M ; Vries, J Bolt-De ; Benraad, ThJ ; Foekens, J A</creatorcontrib><description>The prognostic value of tissue-type plasminogen activator (tPA) measured in samples derived from 865 patients with primary breast cancer using a recently developed enzyme-linked immunosorbent assay (ELISA) was evaluated. Since the assay could easily be adapted to the assessment of the complex of tPA with its type-1 inhibitor (PAI-1), it was investigated whether the tPA:PAI-1 complex also provides prognostic information. To this end, cytosolic extracts and corresponding detergent extracts of 100 000 g pellets obtained after ultracentrifugation when preparing the cytosolic fractions for routine steroid hormone receptor determination were assayed. Statistically significant correlations were found between the cytosolic levels and those determined in the pellet extracts (Spearman correlation coefficient r s = 0.75, P &lt; 0.001 for tPA and r = 0.50, P &lt; 0.001 for tPA:PAI-1 complex). In both Cox univariate and multivariate analysis elevated levels of (total) tPA determined in the pellet extracts, but not in cytosols, were associated with prolonged relapse-free (RFS) and overall survival (OS). In contrast, high levels of the tPA:PAI-1 complex measured in cytosols, but not in the pellet extracts, were associated with a poor RFS and OS. The prognostic information provided by the cytosolic tPA:PAI-1 complex was comparable to that provided by cytosolic (total) PAI-1. Furthermore, the estimated levels of free, uncomplexed tPA and PAI-1, in cytosols and in pellet extracts, were related to patient prognosis in a similar way as the (total) levels of tPA and PAI-1 respectively. Determination of specific forms of components of the plasminogen activation system, i.e. tPA:PAI-1 complex and free, uncomplexed tPA and/or PAI-1, may be considered a useful adjunct to the analyses of the separate components (tPA and/or PAI-1) and provide valuable additional prognostic information with respect to survival of breast cancer patients.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1476-5381</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6690353</identifier><identifier>PMID: 10390010</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Cancer Research ; Cytosol - metabolism ; Drug Resistance ; Enzyme-Linked Immunosorbent Assay ; Epidemiology ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Molecular Medicine ; Multivariate Analysis ; Oncology ; Plasminogen Activator Inhibitor 1 - metabolism ; Prognosis ; Proportional Hazards Models ; Regular ; regular-article ; Survival Analysis ; Tissue Plasminogen Activator - metabolism ; Tumors</subject><ispartof>British Journal of Cancer, 1999-04, Vol.80 (1-2), p.286-294</ispartof><rights>The Author(s) 1999</rights><rights>1999 INIST-CNRS</rights><rights>Copyright © 1999 Cancer Research Campaign 1999 Cancer Research Campaign</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-4e58ff0158b743159401de9a5bf6fb428e2e31b5ae49348124e634959aebe8993</citedby><cites>FETCH-LOGICAL-c477t-4e58ff0158b743159401de9a5bf6fb428e2e31b5ae49348124e634959aebe8993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362996/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362996/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1788735$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10390010$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Witte, J H de</creatorcontrib><creatorcontrib>Sweep, C G J</creatorcontrib><creatorcontrib>Klijn, J G M</creatorcontrib><creatorcontrib>Grebenschikov, N</creatorcontrib><creatorcontrib>Peters, H A</creatorcontrib><creatorcontrib>Look, M P</creatorcontrib><creatorcontrib>Tienoven, ThH van</creatorcontrib><creatorcontrib>Heuvel, J J T M</creatorcontrib><creatorcontrib>Vries, J Bolt-De</creatorcontrib><creatorcontrib>Benraad, ThJ</creatorcontrib><creatorcontrib>Foekens, J A</creatorcontrib><title>Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer</title><title>British Journal of Cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>The prognostic value of tissue-type plasminogen activator (tPA) measured in samples derived from 865 patients with primary breast cancer using a recently developed enzyme-linked immunosorbent assay (ELISA) was evaluated. Since the assay could easily be adapted to the assessment of the complex of tPA with its type-1 inhibitor (PAI-1), it was investigated whether the tPA:PAI-1 complex also provides prognostic information. To this end, cytosolic extracts and corresponding detergent extracts of 100 000 g pellets obtained after ultracentrifugation when preparing the cytosolic fractions for routine steroid hormone receptor determination were assayed. Statistically significant correlations were found between the cytosolic levels and those determined in the pellet extracts (Spearman correlation coefficient r s = 0.75, P &lt; 0.001 for tPA and r = 0.50, P &lt; 0.001 for tPA:PAI-1 complex). In both Cox univariate and multivariate analysis elevated levels of (total) tPA determined in the pellet extracts, but not in cytosols, were associated with prolonged relapse-free (RFS) and overall survival (OS). In contrast, high levels of the tPA:PAI-1 complex measured in cytosols, but not in the pellet extracts, were associated with a poor RFS and OS. The prognostic information provided by the cytosolic tPA:PAI-1 complex was comparable to that provided by cytosolic (total) PAI-1. Furthermore, the estimated levels of free, uncomplexed tPA and PAI-1, in cytosols and in pellet extracts, were related to patient prognosis in a similar way as the (total) levels of tPA and PAI-1 respectively. Determination of specific forms of components of the plasminogen activation system, i.e. tPA:PAI-1 complex and free, uncomplexed tPA and/or PAI-1, may be considered a useful adjunct to the analyses of the separate components (tPA and/or PAI-1) and provide valuable additional prognostic information with respect to survival of breast cancer patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer Research</subject><subject>Cytosol - metabolism</subject><subject>Drug Resistance</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Multivariate Analysis</subject><subject>Oncology</subject><subject>Plasminogen Activator Inhibitor 1 - metabolism</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Regular</subject><subject>regular-article</subject><subject>Survival Analysis</subject><subject>Tissue Plasminogen Activator - metabolism</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1476-5381</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNp1kc9v0zAcxS0EYqVw5QbyASF2SGfHdhJfJlUTPyZNogc4W477TesosYvtFHbhb8cjZYwDJ8t-n_e-X_kh9JKSFSWsuYj9qu3NqqokYYI9QgvK66oQrKGP0YIQUhdEluQMPYuxJySLtXiKzrJV5htZoJ-b4HfOx2QNPuphAuw7nGyMExTp9gD4MOg4Wud34LA2yR518gG_S5v1OdZui22K2PjxMMAP_N2mPU57wHfOgmLr9ra1v_nN-rqg5_kFtwF0TNhoZyA8R086PUR4cTqX6OuH91-uPhU3nz9eX61vCpM3TgUH0XQdoaJpa86okJzQLUgt2q7qWl42UAKjrdDAJeMNLTlUjEshNbTQSMmW6HLOPUztCFsDLgU9qEOwow63ymur_lWc3audP6qSVaWUVQ54ewoI_tsEManRRgPDoB34KapKNiJjPIOrGTTBxxigux9CibqrTMVe5crUqbJseP1wtQf43FEG3pwAHY0eupB_zsa_XN00dQ5aoosZi1lxOwiq91Nw-Vf_P_nV7HA6TQHuE__ovwC7pbpJ</recordid><startdate>19990401</startdate><enddate>19990401</enddate><creator>Witte, J H de</creator><creator>Sweep, C G J</creator><creator>Klijn, J G M</creator><creator>Grebenschikov, N</creator><creator>Peters, H A</creator><creator>Look, M P</creator><creator>Tienoven, ThH van</creator><creator>Heuvel, J J T M</creator><creator>Vries, J Bolt-De</creator><creator>Benraad, ThJ</creator><creator>Foekens, J A</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19990401</creationdate><title>Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer</title><author>Witte, J H de ; Sweep, C G J ; Klijn, J G M ; Grebenschikov, N ; Peters, H A ; Look, M P ; Tienoven, ThH van ; Heuvel, J J T M ; Vries, J Bolt-De ; Benraad, ThJ ; Foekens, J A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-4e58ff0158b743159401de9a5bf6fb428e2e31b5ae49348124e634959aebe8993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer Research</topic><topic>Cytosol - metabolism</topic><topic>Drug Resistance</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Multivariate Analysis</topic><topic>Oncology</topic><topic>Plasminogen Activator Inhibitor 1 - metabolism</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Regular</topic><topic>regular-article</topic><topic>Survival Analysis</topic><topic>Tissue Plasminogen Activator - metabolism</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Witte, J H de</creatorcontrib><creatorcontrib>Sweep, C G J</creatorcontrib><creatorcontrib>Klijn, J G M</creatorcontrib><creatorcontrib>Grebenschikov, N</creatorcontrib><creatorcontrib>Peters, H A</creatorcontrib><creatorcontrib>Look, M P</creatorcontrib><creatorcontrib>Tienoven, ThH van</creatorcontrib><creatorcontrib>Heuvel, J J T M</creatorcontrib><creatorcontrib>Vries, J Bolt-De</creatorcontrib><creatorcontrib>Benraad, ThJ</creatorcontrib><creatorcontrib>Foekens, J A</creatorcontrib><collection>SpringerOpen</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British Journal of Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Witte, J H de</au><au>Sweep, C G J</au><au>Klijn, J G M</au><au>Grebenschikov, N</au><au>Peters, H A</au><au>Look, M P</au><au>Tienoven, ThH van</au><au>Heuvel, J J T M</au><au>Vries, J Bolt-De</au><au>Benraad, ThJ</au><au>Foekens, J A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer</atitle><jtitle>British Journal of Cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1999-04-01</date><risdate>1999</risdate><volume>80</volume><issue>1-2</issue><spage>286</spage><epage>294</epage><pages>286-294</pages><issn>0007-0920</issn><eissn>1476-5381</eissn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>The prognostic value of tissue-type plasminogen activator (tPA) measured in samples derived from 865 patients with primary breast cancer using a recently developed enzyme-linked immunosorbent assay (ELISA) was evaluated. Since the assay could easily be adapted to the assessment of the complex of tPA with its type-1 inhibitor (PAI-1), it was investigated whether the tPA:PAI-1 complex also provides prognostic information. To this end, cytosolic extracts and corresponding detergent extracts of 100 000 g pellets obtained after ultracentrifugation when preparing the cytosolic fractions for routine steroid hormone receptor determination were assayed. Statistically significant correlations were found between the cytosolic levels and those determined in the pellet extracts (Spearman correlation coefficient r s = 0.75, P &lt; 0.001 for tPA and r = 0.50, P &lt; 0.001 for tPA:PAI-1 complex). In both Cox univariate and multivariate analysis elevated levels of (total) tPA determined in the pellet extracts, but not in cytosols, were associated with prolonged relapse-free (RFS) and overall survival (OS). In contrast, high levels of the tPA:PAI-1 complex measured in cytosols, but not in the pellet extracts, were associated with a poor RFS and OS. The prognostic information provided by the cytosolic tPA:PAI-1 complex was comparable to that provided by cytosolic (total) PAI-1. Furthermore, the estimated levels of free, uncomplexed tPA and PAI-1, in cytosols and in pellet extracts, were related to patient prognosis in a similar way as the (total) levels of tPA and PAI-1 respectively. Determination of specific forms of components of the plasminogen activation system, i.e. tPA:PAI-1 complex and free, uncomplexed tPA and/or PAI-1, may be considered a useful adjunct to the analyses of the separate components (tPA and/or PAI-1) and provide valuable additional prognostic information with respect to survival of breast cancer patients.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>10390010</pmid><doi>10.1038/sj.bjc.6690353</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British Journal of Cancer, 1999-04, Vol.80 (1-2), p.286-294
issn 0007-0920
1476-5381
1532-1827
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2362996
source Wiley; PubMed Central
subjects Adult
Aged
Aged, 80 and over
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Cancer Research
Cytosol - metabolism
Drug Resistance
Enzyme-Linked Immunosorbent Assay
Epidemiology
Female
Gynecology. Andrology. Obstetrics
Humans
Mammary gland diseases
Medical sciences
Middle Aged
Molecular Medicine
Multivariate Analysis
Oncology
Plasminogen Activator Inhibitor 1 - metabolism
Prognosis
Proportional Hazards Models
Regular
regular-article
Survival Analysis
Tissue Plasminogen Activator - metabolism
Tumors
title Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A45%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20tissue-type%20plasminogen%20activator%20(tPA)%20and%20its%20complex%20with%20the%20type-1%20inhibitor%20(PAI-1)%20in%20breast%20cancer&rft.jtitle=British%20Journal%20of%20Cancer&rft.au=Witte,%20J%20H%20de&rft.date=1999-04-01&rft.volume=80&rft.issue=1-2&rft.spage=286&rft.epage=294&rft.pages=286-294&rft.issn=0007-0920&rft.eissn=1476-5381&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6690353&rft_dat=%3Cproquest_pubme%3E69859634%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c477t-4e58ff0158b743159401de9a5bf6fb428e2e31b5ae49348124e634959aebe8993%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=69859634&rft_id=info:pmid/10390010&rfr_iscdi=true